Clinical Trial Details
— Status: Completed
Administrative data
NCT number |
NCT05048953 |
Other study ID # |
IERB No 132(6-1)t2, 078/079 |
Secondary ID |
|
Status |
Completed |
Phase |
|
First received |
|
Last updated |
|
Start date |
October 1, 2021 |
Est. completion date |
November 1, 2022 |
Study information
Verified date |
December 2023 |
Source |
B.P. Koirala Institute of Health Sciences |
Contact |
n/a |
Is FDA regulated |
No |
Health authority |
|
Study type |
Observational [Patient Registry]
|
Clinical Trial Summary
Intensive Care Unit-Acquired Weakness (ICU-AW) is a clinical entity frequently encountered in
critically ill patients that have both short term and long-term implications.
The current gold standard of diagnosis is by assessment of manual muscle strength, using the
6-grade Medical Research Council (MRC) sum score. However, not all Intensive Care Unit (ICU)
admitted patients are conscious or cooperative enough to use MRC sum score for the diagnosis
of ICU-AW. Ultrasound imaging of muscles has emerged as a valid and reliable tool for
providing qualitative and quantitative details about muscle disease and has been suggested as
an alternative to assess ICU-AW in critically ill patients in whom the MRC cannot be
assessed. This study will be a prospective observational study to evaluate the relationship
between the trend of changes in muscle thickness, echogenicity and fasciculations during the
first 7 days of ICU stay as measured by ultrasound and ICU-AW among critically ill patients.
The study will be performed in the ICU of TU Teaching Hospital, Kathmandu, Nepal for 1 year.
All newly admitted adult patients ≥ 16 years of age, expected to stay in ICU / critical care
areas for at least 7 days, barring the exclusion criteria, will be included in the study and
evaluated for MRC sum score and skeletal muscle thickness, echogenicity and fasciculations
using ultrasound on day 1, day 4 and day 7. The measurements will then be statistically
analyzed to see if there is any relationship between trend of changes in muscle thickness,
echogenicity and fasciculations and ICU-AW
Description:
All newly admitted patients (shifted to ICU within 48 h of hospital admission), aged ≥ 16
years and expected to stay in ICU or critical care areas for 7 days will be included in the
study after excluding those who fulfill excluding criterial. In all the participants, muscle
strength will be assessed at day 1, day 4 and day 7, if the patients are awake as assessed by
Richmond Agitation Sedation Scale (RASS) (19) between -1 and 1, and cooperative (20) assessed
by being able to follow at least 3 out of 5 verbal commands with facial muscles (scored by
the Score of 5 Questions). Assessment will be done by an ICU physician blinded to the result
of ultrasound. The MRC score will be used for assessment of strength in the following six
muscle groups bilaterally: wrist dorsiflexors, elbow flexors, shoulder abductors, hip
flexors, knee extensors and ankle dorsiflexors. ICU-AW will be defined as MRC sum score < 48,
in accordance with the international consensus statement.(1) Muscle ultrasound measurements
(the index test) Muscle ultrasound will be performed by an ICU faculty or a DM resident of
Critical care medicine (who has an experience of at least 25 muscle ultrasonography with at
least 10 muscle ultrasonography performed under supervision) (21) and will be blinded to the
result of MRC score of the patient. Muscle ultrasound images on day 1, day 4 and day 7 will
be obtained in the participants, using Mindray DC-60® portable ultrasound machine, with a 9
to 13 MHz linear probe. The device settings include MSK pre-set, and will be kept constant
during all examinations. The depth can be altered individually when deeper view is required
to visualize the entire muscle thickness. Patients will be examined in the supine position
with extended upper, lower limbs and completely relaxed muscles. The relaxation of muscle
will be ensured by scanning the muscle in the sagittal view. A contracted muscle will show
bulging in the central portion with thinning of its more distal ends. The angle of pennation
can be seen to change as the muscle moves through its range of motion and the interosseous
membrane will show bulging. A generous amount of contact gel will be used to minimize the
required pressure of the transducer on the skin. Compression of the tissue will be avoided as
it can affect the quality of muscle images. Transverse images of each muscle will be obtained
with the transducer perpendicular to the direction of muscle fibre orientation.
The following parameters will be measured by muscle ultrasound
1. Muscle thickness
2. Muscle echogenicity
3. Muscle fasciculations Muscle thickness Measurements will be made using the built-in
electronic calipers on a frozen, real time, cross section image over the largest bulk
visible to eye. 3 measurements will be taken at each site and the mean value used for
statistical analysis. The following anatomical sites will be assessed bilaterally: (22)
- The biceps brachii muscle including the underlying brachialis muscle
- The forearm flexor group
- The quadriceps femoris muscle
- The tibialis anterior muscle Muscle echogenicity The muscle echogenicity will be
assessed by muscle ultrasound and graded according to Heckmatt and colleagues into
four grades:(16) Grade I: Normal echo intensity with starry-night aspect with
distinct bone echo.
Grade II: Increased echo intensity with normal bone echo. Grade III: Increased echo intensity
with reduced bone signal. Grade IV: Increased echo intensity and loss of bone signal Muscle
fasciculations The muscle fasciculations will be detected by ultrasound.(18) Each muscle will
be examined over a time period of 10 seconds. The movement of fasciculation will be defined
as twitching of small parts of the muscle lasting for 0.2-0.5 s, at least two of which will
be required to be classified as being present. A fasciculation score ranges from 0 to 4 which
is the number of regions with fasciculations out of four muscle regions. All the participants
will be managed according to the ICU protocol of TUTH and there will be no variation in
treatment between those allocated to study and those not allocated to the study.